Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAOL2S)

Drug Name
Voriconazole Drug Info
Synonyms
VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
Indication
Disease Entry ICD 11 Status REF
Aspergillosis 1F20 Approved [1]
Candidiasis 1F23 Approved [1]
Fusariosis Approved [1]
Invasive aspergillosis 1F20.0 Approved [2]
Invasive candidiasis 1F23 Approved [1]
Neuroaspergillosis Approved [1]
Candidemia 1F23.3Y Investigative [1]
Esophageal candidiasis Investigative [1]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
71616
ChEBI ID
CHEBI:10023
CAS Number
CAS 188416-29-7
TTD Drug ID
DMAOL2S
VARIDT Drug ID
DR00445
INTEDE Drug ID
DR1709
ACDINA Drug ID
D00733

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Candida Cytochrome P450 51 (Candi ERG11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [3]
Posaconazole DMUL5EW Aspergillosis 1F20 Approved [11]
Ketoconazole DMPZI3Q Blastomycosis 1F22 Approved [12]
Miconazole DMPMYE8 Cutaneous candidiasis 1F23.14 Approved [3]
Oxiconazole DME7KRM Tinea corporis 1F28.Y Approved [13]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [3]
Terconazole DMJ13KI Candidiasis 1F23 Approved [14]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [15]
Tioconazole DMNYPGS Onychomycosis EE12.1 Approved [16]
Econazole DMFSWGH Cutaneous candidiasis 1F23.14 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [17]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [18]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [19]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [20]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [21]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [22]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [23]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [24]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [18]
Verapamil DMA7PEW Angina pectoris BA40 Approved [6]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [42]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [44]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [45]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [45]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [46]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [47]
Capsaicin DMGMF6V Back pain ME84.Z Approved [48]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [49]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [50]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [25]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [26]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [27]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [29]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [28]
Verapamil DMA7PEW Angina pectoris BA40 Approved [30]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [31]
Estrone DM5T6US Acne vulgaris ED80 Approved [32]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [51]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [45]
Capsaicin DMGMF6V Back pain ME84.Z Approved [52]
Zafirlukast DMHNQOG Asthma CA23 Approved [53]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [45]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [54]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [9]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [45]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [20]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [34]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [25]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [35]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [36]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [28]
Verapamil DMA7PEW Angina pectoris BA40 Approved [37]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [38]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [39]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [6]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [6]
Diazepam DM08E9O Alcohol withdrawal Approved [6]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [6]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [6]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [6]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [6]
Ketobemidone DMM3L6Z Pain MG30-MG3Z Approved [6]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [55]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [56]
Capsaicin DMGMF6V Back pain ME84.Z Approved [52]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [45]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [57]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [45]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [55]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [58]
Clobazam - Lundbeck DMW1OQ0 Anxiety disorder 6B00-6B0Z Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Carbonic anhydrase 1 (CA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [60]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [61]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [62]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [63]
Candesartan DMRK8OT Chronic heart failure BD1Z Approved [61]
Indomethacin DMSC4A7 Bursitis Approved [64]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [65]
Phenylephrine DMZHUO5 Allergic rhinitis CA08.0 Approved [66]
GUAIACOL DMN4E7T N. A. N. A. Phase 3 [62]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Carbonic anhydrase 2 (CA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetazolamide DM1AF5U Absence epilepsy Approved [64]
Epinephrine DM3KJBC Acute asthma CA23 Approved [68]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [70]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [71]
Methazolamide DM7J2TA Glaucoma/ocular hypertension 9C61 Approved [72]
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [73]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [74]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [75]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [76]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [77]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [78]
Estrone DM5T6US Acne vulgaris ED80 Approved [79]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [80]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [81]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [82]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [83]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [84]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lanosterol 14-alpha demethylase (CYP51A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [85]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [86]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [86]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [87]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [88]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [89]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [90]
Testosterone DM7HUNW Hot flushes GA30 Approved [91]
Leflunomide DMR8ONJ Arthritis FA20 Approved [92]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 2C9 (CYP2C9) Main DME DE5IED8 CP2C9_HUMAN Substrate [5]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME DEGTFWK CP2CJ_HUMAN Substrate [5]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Carbonic anhydrase 1 (CA1) OTNFBVVQ CAH1_HUMAN Gene/Protein Processing [7]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Gene/Protein Processing [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [8]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [9]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [9]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [9]
Lanosterol 14-alpha demethylase (CYP51A1) OTAYHG9C CP51A_HUMAN Drug Response [10]

References

1 Voriconazole FDA Label
2 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
5 Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 Inhibition profiles of Voriconazole against acetylcholinesterase, -glycosidase, and human carbonic anhydrase I and II isoenzymes. J Biochem Mol Toxicol. 2019 Oct;33(10):e22385. doi: 10.1002/jbt.22385. Epub 2019 Sep 3.
8 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
9 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
10 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
11 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
12 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
13 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
14 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
15 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
16 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
17 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
26 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
27 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
28 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
29 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
30 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
31 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
32 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
33 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
34 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
35 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
36 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
37 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
38 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
39 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
40 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
41 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
42 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
43 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
44 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
45 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
46 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
47 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
48 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
49 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
50 Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
51 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
52 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
53 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
54 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
55 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
56 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
57 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
58 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
59 In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
60 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
61 The mechanism of action of angiotensin II is dependent on direct activation of vascular smooth muscle carbonic anhydrase I. Int J Clin Lab Res. 2000;30(3):119-25. doi: 10.1007/s005990070010.
62 Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols bioorg. Med Chem. 2009 Apr 15;17(8):3207-11.
63 Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
64 Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action. Int J Clin Pharmacol Ther. 2001 Jun;39(6):265-70.
65 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
66 Synephrine and phenylephrine act as -amylase, -glycosidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase enzymes inhibitors. J Biochem Mol Toxicol. 2017 Nov;31(11). doi: 10.1002/jbt.21973. Epub 2017 Aug 11.
67 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
68 Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta. 2003 May 12;1640(2-3):137-42.
69 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
70 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
71 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
72 Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen. 2006 Oct;11(7):782-91.
73 Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem. 2011 Mar 10;54(5):1481-9.
74 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
75 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
76 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
77 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
78 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
79 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
80 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
81 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
82 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
83 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
84 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
85 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
86 Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology. 2006 Nov 10;228(1):24-32. doi: 10.1016/j.tox.2006.08.007. Epub 2006 Aug 12.
87 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
88 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
89 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
90 JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
91 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
92 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.